ÐÂÎÅÖÐÐÄ
News Center
Ò»Ïß·ÎÁÛ°©¢óÆÚÁÙ´²Àֳɣ¡±´ÄªËհݵ¥¿¹ÍŽᰲÂÞÌæÄáÐÂ˳Ӧ֢½«É걨ÉÏÊÐ
Ðû²¼Ê±¼ä£º2024-12-27
¿ËÈÕ£¬£¬£¬£¬£¬£¬HJC»Æ½ð³Ç¹Ù·½ÍøÕ¾1ÀàÁ¢ÒìÒ©±´ÄªËհݵ¥¿¹×¢ÉäҺ͎áÑÎËá°²ÂÞÌæÄὺÄÒµÄÓÖÒ»Ïî¢óÆÚÁÙ´²Ñо¿£¨TQB2450-¢ó-12£©È¡µÃÑôÐÔЧ¹û£¬£¬£¬£¬£¬£¬²¢»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ÊéÃæÔ޳ɣ¬£¬£¬£¬£¬£¬½«ÓÚ½üÆÚÌá½»ÐÂ˳Ӧ֢µÄÉÏÊÐÉêÇë¡£¡£¡£¡£¡£¡£¡£¡£ÐÂ˳Ӧ֢ΪһÏßÖÎÁÆÍíÆÚÁÛ×´·ÇСϸ°û·Î°©£¨sq-NSCLC£©¡£¡£¡£¡£¡£¡£¡£¡£
![]()
2022ÄêÈ«Çò°©Ö¢Êý¾Ýͳ¼Æ£¬£¬£¬£¬£¬£¬·Î°©ÔÚÈ«ÇòºÍÖйúµÄ·¢²¡Âʼ°éæÃüÂÊÔ¢ËùÓжñÐÔÖ×ÁöµÄµÚһ룬£¬£¬£¬£¬£¬ÆäÖзÇСϸ°û·Î°©£¨NSCLC£©Õ¼ËùÓзΰ©µÄ80%-85%[1]¡£¡£¡£¡£¡£¡£¡£¡£ÁÛ×´·ÇСϸ°û·Î°©£¨sq-NSCLC£©ÊÇNSCLCµÄÖ÷ÒªÑÇÐÍÖ®Ò»£¬£¬£¬£¬£¬£¬Ô¼Õ¼ËùÓÐNSCLCµÄ30%[2]¡£¡£¡£¡£¡£¡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬£¬£¬sq-NSCLC»¼Õ߿ɽÓÊܰÐÏòÖÎÁƵİеãÍ»±äÂÊȱ·¦10%£¬£¬£¬£¬£¬£¬´ó¶¼»¼ÕßÄÑÒÔ´Ó°ÐÏòÖÎÁÆÖлñÒæ[3,4]¡£¡£¡£¡£¡£¡£¡£¡£ËäÈ»ÃâÒßÍŽữÁÆÒѳÉΪsq-NSCLCµÄ±ê×¼ÖÎÁÆÄ£Ê½£¬£¬£¬£¬£¬£¬µ«ÁÙ´²Ð§¹ûÈÔÈ»ÓÐÏÞ£¬£¬£¬£¬£¬£¬Ø½´ý¿ª·¢ÐµÄÖÎÁƼƻ®½øÒ»²½¸ÄÉÆ»¼ÕßÔ¤ºó¡£¡£¡£¡£¡£¡£¡£¡£
TQB2450-¢ó-12£¨NCT05718167£©ÊÇÒ»Ïî¶àÖÐÐÄ¡¢Ëæ»ú¡¢Ë«Ã¤¡¢Æ½ÐбÈÕյĢóÆÚÁÙ´²Ñо¿£¬£¬£¬£¬£¬£¬Ö¼ÔÚÆÀ¹À±´ÄªËհݵ¥¿¹×¢ÉäҺ͎ữÁƺóÐò¹áÍŽáÑÎËá°²ÂÞÌæÄὺÄÒ±ÈÕÕÌæÀ×ÀûÖéµ¥¿¹×¢ÉäҺ͎ữÁÆÒ»ÏßÖÎÁÆÍíÆÚÁÛ×´·ÇСϸ°û·Î°©£¨sq-NSCLC£©µÄÓÐÓÃÐÔºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£¡£¾×ÔÁ¦Êý¾Ý¼à²éίԱ»á£¨IDMC£©Åжϣ¬£¬£¬£¬£¬£¬Ö÷ÒªÑо¿ÖÕµãÎÞÏ£ÍûÉúÑÄÆÚ£¨PFS£©µÖ´ï¼Æ»®Ô¤ÉèµÄÓÅЧ½çÖµ¡£¡£¡£¡£¡£¡£¡£¡£
±¾Ñо¿µÄÆÚÖÐÆÊÎöЧ¹ûÏÔʾ£¬£¬£¬£¬£¬£¬ÓëÌæÀ×ÀûÖéµ¥¿¹ÍŽữÁÆ×éÏà±È£¬£¬£¬£¬£¬£¬±´ÄªËհݵ¥¿¹ÍŽữÁƺóÐò¹áÍŽᰲÂÞÌæÄá¿ÉÏÔÖøÑÓÉ컼ÕßµÄmPFS£¬£¬£¬£¬£¬£¬½µµÍ¼²²¡Ï£Íû»òéæÃüΣº¦¡£¡£¡£¡£¡£¡£¡£¡£ÆäÇå¾²ÐÔÊý¾ÝÓëÒÑ֪Σº¦Ïà·û£¬£¬£¬£¬£¬£¬Î´·¢Ã÷еÄÇå¾²ÐÔÐźš£¡£¡£¡£¡£¡£¡£¡£±¾Ñо¿ÊÇÈ«ÇòÊ׸ö±ÈÕÕÃâÒßPD-1ÍŽữÁÆÒ»ÏßÖÎÁÆsq-NSCLCÈ¡µÃÑôÐÔЧ¹ûµÄ¢óÆÚÁÙ´²Ñо¿¡£¡£¡£¡£¡£¡£¡£¡£HJC»Æ½ð³Ç¹Ù·½ÍøÕ¾½«ÓÚ½üÆÚ¿ªÕ¹µÄ¹ú¼ÊȨÍþѧÊõ´ó»áÐû²¼ÏêϸÑо¿Êý¾Ý¡£¡£¡£¡£¡£¡£¡£¡£
±´ÄªËհݵ¥¿¹ÍŽữÁƺóÐò¹áÍŽáÑÎËá°²ÂÞÌæÄὺÄÒÓÃÓÚÍíÆÚÁÛ×´·ÇСϸ°û·Î°©Ò»ÏßÖÎÁÆÊÇÑÎËá°²ÂÞÌæÄὺÄÒ¼´½«É걨ÉÏÊеĵÚ13¸ö˳Ӧ֢¡¢±´ÄªËհݵ¥¿¹×¢ÉäÒº¼´½«É걨ÉÏÊеĵÚ6¸ö˳Ӧ֢¡£¡£¡£¡£¡£¡£¡£¡£Õâһ͎áÁÆ·¨ÓÃÓÚÖÎÁÆÆÕ±éÆÚСϸ°û·Î°©µÄ˳Ӧ֢ÒÑ»ñÅúÉÏÊУ¬£¬£¬£¬£¬£¬Ò»ÏßÖÎÁÆÉöϸ°û°©µÄ˳Ӧ֢ÒÑÌá½»ÉÏÊÐÉêÇ룬£¬£¬£¬£¬£¬¶àÏî·ÇСϸ°û·Î°©ÁìÓòµÄ¢óÆÚÑо¿ÕýÔÚ¿ªÕ¹¡£¡£¡£¡£¡£¡£¡£¡£HJC»Æ½ð³Ç¹Ù·½ÍøÕ¾µÄ“ÃâÒßÍŽΌѪ¹ÜÌìÉúÖÎÁƔģʽ½«ÎªÖ×Áö»¼Õß´øÀ´¸ü¶àÖÎÁÆÏ£Íû¡£¡£¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2024, 74(3): 229-263.
[2] Hirsh V. New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther. 2017 May 11;10:2513-2526.
[3] Yuan H, Lu S. Research status on targeted therapy for squamous cell lung cancer. Zhongguo Fei Ai Za Zhi. 2013 Oct 20;16(10):559-63.
[4] Gao M, Zhou Q. Progress in Treatment of Advanced Squamous Cell Lung Cancer. Zhongguo Fei Ai Za Zhi. 2020 Oct 20;23(10):866-874.
¡ø ÉÏÏ»¬¶¯Éó²é¸ü¶à
ÉùÃ÷£º
1.ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬£¬£¬£¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬£¬£¬£¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£¡£¡£¡£
2.±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍÆ¼ö¡£¡£¡£¡£¡£¡£¡£¡£
3.±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬£¬£¬£¬£¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬£¬£¬£¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬£¬£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£¡£¡£¡£
ǰհÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉǰհÐÔ³ÂÊö£¬£¬£¬£¬£¬£¬°üÀ¨Óйء¾±´ÄªËհݵ¥¿¹×¢ÉäÒº¡¢ÑÎËá°²ÂÞÌæÄὺÄÒ¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢ÁÙ´²»ñÒæÓëÓÅÊÆµÄÔ¤ÆÚ¡¢ÉÌÒµ»¯Õ¹Íû¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬£¬£¬£¬£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡£¡£¡£¡£¡£¡£¡£“Ô¤ÆÚ”¡¢“ÏàÐÅ”¡¢“¼ÌÐø”¡¢“¿ÉÄÜ”¡¢“Ô¤¼Æ”¡¢“ÆÚÍû”¡¢“ÓÐÍû”¡¢“ÍýÏ딡¢“ÍýÏ딡¢“DZÔÚ”¡¢“Õ¹Íû”¡¢“Ô¤¼Æ”¡¢“Ó¦¸Ã”¡¢“½«”¡¢“Ä┡¢“»á”ºÍÀàËÆ±í´ïÖ¼ÔÚʶ±ðǰհÐÔ³ÂÊö£¬£¬£¬£¬£¬£¬µ«²¢·ÇËùÓÐǰհÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡£¡£¡£¡£¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÕ¹Íû»òÆÚÍû£¬£¬£¬£¬£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢Ñз¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»òΣº¦µÄÓ°Ï죬£¬£¬£¬£¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëǰհÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡£¡£¡£¡£¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄΣº¦£¬£¬£¬£¬£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄǰհÐÔ³ÂÊö£¬£¬£¬£¬£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡£¡£¡£¡£¡£¡£¡£³ý·ÇÖ´·¨ÒªÇ󣬣¬£¬£¬£¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎǰհÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡£¡£¡£¡£¡£¡£¡£
